Table 3.
Published five year survival estimates (%) with 95% confidence intervals (in parentheses) for teenagers and young adults.
| Publication | Country (diagnosis period and population coverage §) | Age range | ALL | AML | NHL | Hodgkin lymphoma | CNS | Osteosarcoma | Ewing sarcoma | Rhabdomyosarcoma | Gonadal GCT | Non-gonadal GCT | Melanoma | Breast (female) | Cervix | Colorectal |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| This publication | UK (2002–2006; fp) | 15–24 | 62.0 (57–2-66.5) | 60.4 (54.4–65.9) | 78.4 (74.9–81.4) | 93.6 (92.1–94.8) | 79.3 (77.0–81.5) | 54.0 (46.9–60.5) | 45.8 (38.5–52.8) | 35.1 (24.8–45.5) | 96.3 (95.1–97.2) | 81.3 (72.2–87.7) | 93.7 (92.0–95.0) | 82.1 (73.0–88.5) | 87.8 (82.9–91.3) | 68.0 (62.0–73.2) |
| 15–19 | 64.7 (58.9–69.9) | 61.5 (52.5–69.4) | 81.5 (76.3–85.6) | 93.1 (90.7–94.9) | 81.0 (77.6–83.9) | 61.0 (52.3–68.5) | 44.9 (35.3–54.1) | 36.8 (23.6–50.0) | 94.5 (91.7–96.4) | 86.7 (73.9–93.5) | 92.6 (88.8–95.1) | 78.0 (36.6–94.2) | 66.9 (28.3–88.1) | 84.9 (72.9–91.9) | ||
| 20–24 | 56.9 (48.0–64.9) | 59.5 (51.3–66.8) | 76.0 (71.2–80.1) | 94.0 (92.0–95.5) | 78.4 (75.1–81.3) | 39.8 (28.2–51.2) | 46.9 (35.6–57.5) | 32.3 (17.0–48.7) | 97.0 (95.7–97.9) | 75.7 (61.0–85.4) | 94.1 (92.2–95.6) | 82.9 (73.5–89.3) | 80.7 (74.8–85.3) | 63.6 (56.7–69.8) | ||
| Gondos et al. (2013) | USA (2002–2006; pp) | 15–29 | 50.9 (46.0–55.8) | 46.7 (41.8–51.6) | 78.2 (75.7–80.7) | 93.1 (91.7–94.5) | 64.7 (58.8–70.6) | 50.7 (43.3–58.1) | 96.0 (95.0–97.0) | 77.1 (69.8–84.4) | 96.0 (95.0–97.0) | 80.2 (76.9–83.5) | 86.9 (84.2–89.6) | 63.7 (59.0–68.4) | ||
| Germany (2002–2006; pp) | 15–29 | 57.2 (50.5–63.9) | 58.1 (50.5–65.7) | 84.5 (81.0–88.0) | 97.9 (96.9–98.9) | 69.1 (61.1–77.1) | 49.7 (40.1–59.3) | 97.2 (96.2–98.2) | 79.9 (70.3–89.5) | 96.7 (95.5–97.9) | 81.5 (76.8–86.2) | 90.4 (86.7–94.1) | 68.9 (61.5–76.3) | |||
| AIRTUM (2013) | Italy (2003–2008; pp) | 15–19 | 74 | 77 | 88 | 95 | 81 | 59 | 28 | 100 | 95 | |||||
| Desandes et al. (2013) | France (2000–2004; pp) | 15–24 | 62.8 (50.0–73.2) | 56.8 (39.4–70.8) | 78.9 (67.4–86.7) | 96.9 (93.6–98.5) | 67.3 (57.1–75.7) | 38.7 (22.0–55.1) | 56.5 (34.3–73.8) | 35.7 (13.0–59.4) | 92.8 (88.7–96.9) | 92.7 (85.3–96.5) | ||||
| Pole et al. (2013) | Canada (2004–2009; pp) | 15–19 | 76 (65–89) | |||||||||||||
| 20–29 | 69 (56–83) | |||||||||||||||
| Carreira et al. (2012) | Portugal (1997–2006; pp) | 15–19 | 50.0 (27.1–69.2) ≈ | 46.1 (19.2–69.6) acute non-lymphoblastic | 67.9 (47.3–81.8)(excludes Burkitt) | 96.7 (90.1–98.9) | 56.4 (38.3–71.0) n/a | 70.0 (45.1–85.3) | 60.0 (31.8–79.7) includes related sarcomas | 27.3 (0.07–53.9) | 94.1 (78.5–98.5) | 62.5 (22.9–86.1) | 91.7 (53.9–98.9) | insuff cases | insuff cases | 50.0 (15.2–77.5) |
| 20–24 | 50.0 (22.9–72.2) ≈ | 44.4 (21.6–65.1) | 61.2 (44.1–74.5) | 94.8 (88.7–97.6) | 83.1 (71.5–90.3) n/a | 75.0 (40.8–91.2) | 28.6 (4.1–61.2) | Insuff cases | 94.7 (87.7–97.8) | 54.6 (22.9–78.0) | 83.3 (61.5–93.4) | 68.0 (42.1–84.2) | 92.3 (56.6–98.9) | 76.5(48.8–90.5) | ||
| Bleyer (2011) | USA (2000–2007; pp) | 15–39 | 49.1 (45.2–53.0) | 49.4 (44.1–54.7) | 74.6 (72.3–77.0) | 92.2 (90.6–93.8) | 64.6 (61.3–67.9) n/a | 65.8 (57.4–74.2) | 51.4 (40.6–62.2) | 38.1 (26.3–49.9) | 94.1 (93.1–95.1) | 82.5 (81.3–83.7) | 82.0 (80.0–84.0) | 65.9 (63.2–68.6) | ||
| Pinkerton et al. (2010) | Australia (2000–2004; fp) | 15–19 | 73.6 (62.5–81.8) | 74.2 (61.3–83.3) | 83.3 (75.3–88.9) | 97.5 (94.0–98.9) | ||||||||||
| 20–29 | 47.1 (34.5–58.6) | 62.5 (54.1–69.8) | 81.1 (76.6–84.8) | 95.1 (92.5–96.8) | ||||||||||||
| Gatta et al. (2009) | Europe (2000–2002) | 15–24 | 49.5 (42.5–56.5) | 59.1 (50.3–67.9) | 74.4 (69.2–79.5) | 93.1 (91.4–94.9) | 61.7 (56.5–67.0) n/a | 59.8 (51.2–68.5) | 48.0 (35.3–60.6) | 92.2 (89.6–94.9) | 85.5 (79.2–91.8) | 85.7 (73.2–98.1) | ||||
| UK and Ireland | 52.6 (47.3–57.8) | 49.1 (43.6–54.7) | 69.6 (65.0–74.2) | 92.9 (91.4–94.3) | 57.2 (52.9–61.4) n/a | 54.9 (47.3–62.5) | 41.8 (33.1–50.5) | 91.3 (89.3–93.2) | 67.4 (58.7–76.1) | 82.0 (76.5–87.5) | ||||||
| Central Europe | 50.1 (42.4–57.8) | 47.4 (37.4–57.8) | 69.4 (63.1–75.8) | 94.7 (92.8–96.7) | 62.1 (55.5–68.8) n/a | 66.7 (56.8–76.6) | 47.0 (33.0–61.0) | 93.4 (90.0–95.9) | 80.6 (69.6–91.6) | 93.6 (87.5–99.8) | ||||||
| Southern Europe | 51.7 (43.5–59.9) | 47.8 (38.8–56.8) | 73.4 (68.5–78.3) | 93.5 (91.6–95.4) | 57.0 (50.7–63.3) n/a | 60.1 (49.6–70.6) | 33.6 (22.0–45.2) | 92.8 (89.9–95.7) | 75.8 (64.9–86.7) | 81.0 (63.9–98.1) | ||||||
| Eastern Europe | 60.4 (38.6–82.2) | 45.6 (17.6–73.5) | 71.8 (57.4–86.2) | 93.4 (89.2–97.7) | 64.2 (51.0–77.5) n/a | 52.0 (25.5–78.5) | 50.0 (18.4–81.6) | 86.3 (74.9–97.7) | 83.3 (61.8–100) | |||||||
| Northern Europe | 59.5 (51.9–67.1) | 47.0 (37.0–57.0) | 74.8 (68.6–81.0) | 95.4 (93.6–97.1) | 65.5 (59.9–71.1) n/a | 63.2 (52.3–74.1) | 58.0 (40.8–75.2) | 97.2 (95.6–98.8) | 78.2 (62.4–94.1) | 91.2 (84.9–97.6) |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; NHL, non-Hodgkin lymphoma; GCT, germ cell tumour; CNS, central nervous system tumour. Survival rates with 95% confidence intervals (CI) that do not overlap with those for the UK are indicated in bold type. 95% CIs not included in the original publication have been calculated from the published standard error (SE) where available. CNS tumour rates for the UK include benign and borderline tumours. Where CNS tumour rates for other countries include only malignant tumours the comparison is indicated as n/a. §: Population coverage is indicated for each country as fp (full population) or pp (partial population).